Alle verbonden artikelen

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial.

Auteurs : Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber Rd, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(16)
Pagina's : 1954-60

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Auteurs : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Jaar : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pagina's : R86

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Auteurs : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Jaar : 2013
Journal : Future Oncol
Volume : 9(10)
Pagina's : 1477-87

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

Auteurs : Von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, Awada A
Jaar : 2013
Journal : Crit Rev Oncol Hematol
Volume : 85(3)
Pagina's : 315-31

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Auteurs : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbier G, Fried M, Awada A, Piccart-Gebhart M, Laethem JL, Flamen P
Jaar : 2013
Journal : BMC Cancer
Volume : 13(1)
Pagina's : 190

Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Auteurs : Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JL, de Azambuja E, El Saghir NS, Kaur R, McTiernan A, Partridge AH, Rowland JH, Singh-Carlson S, Vargo MM, Thompson B, Anderson BO
Jaar : 2013
Journal : Breast
Volume : 22(5)
Pagina's : 606-15

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Auteurs : Goss PE, Smith IE, + collaborators (among others :, Piccart-Gebhart M, Finkelstein DM
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(1)
Pagina's : 88-96

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.

Auteurs : El Hajj P, Journe F, Wiedig M, Laios I, Sales F, Galibert MD, Van Kempen LC, Spatz A, Badran B, Larsimont D, Awada A, Ghanem G
Jaar : 2013
Journal : Br J Cancer
Volume : 108(8)
Pagina's : 1641-7

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Auteurs : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Jaar : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pagina's : 1862-8

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Auteurs : Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart M, Schellens JH, Awada A
Jaar : 2013
Journal : Cancer Chemother Pharmacol
Volume : 71(1)
Pagina's : 53-62

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : Ann Oncol
Volume : 24(2)
Pagina's : 377-84

Targeted therapies of solid cancers: new options, new challenges.

Auteurs : Awada A, Aftimos P
Jaar : 2013
Journal : Curr Opin Oncol
Volume : 25(3)
Pagina's : 296-304

Clinical practice-changing trials: the HERA study paradigm.

Auteurs : Zardavas D, Ades F, de Azambuja E
Jaar : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(11)
Pagina's : 1249-56

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Auteurs : Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart-Gebhart M, Peccatori FA
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(1)
Pagina's : 73-9

Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges.

Auteurs : Alameddine RS, Otrock ZK, Awada A, Shamseddine A
Jaar : 2013
Journal : Curr Opin Oncol
Volume : 25(3)
Pagina's : 313-24

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Auteurs : Zardavas D, Cameron D, Krop I, Piccart-Gebhart M
Jaar : 2013
Journal : Am Soc Clin Oncol Educ Book
Volume : null(null)

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Auteurs : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Jaar : 2013
Journal : Ann Oncol
Volume : 24(11)
Pagina's : 2897-902

Stratified Medicine: a call for action

Auteurs : Awada A, Annemans L, Broeckx D, Pauwels P, Simoens S, Van Belle S, van Cutsem E, Van Hoof E, De Greve J
Jaar : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pagina's : 15-19

Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints.

Auteurs : Hendlisz A, Charette N, Awada A, Deleporte A
Jaar : 2013
Journal : Curr Opin Oncol
Volume : 25(4)
Pagina's : 407-8

Emerging targeted agents in metastatic breast cancer.

Auteurs : Zardavas D, Baselga J, Piccart-Gebhart M
Jaar : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(4)
Pagina's : 191-210